Compare Stocks: SLXN, SNGX, ENLV, and LIMN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$0.21 -3.8%	$1.07	$0.21 ▼ $27.15	$3.74M	1.42	356,285 shs	455,112 shs
LIMN Liminatus Pharma	$3.35 -1.9%	$4.37	$3.27 ▼ $141.50	$4.48M	4.97	339,708 shs	17,101 shs
SLXN Silexion Therapeutics	$0.17 -3.4%	$0.47	$0.16 ▼ $38.20	$945K	-0.29	3.44 million shs	485,697 shs
SNGX Soligenix	$0.34 +1.9%	$0.38	$0.28 ▼ $1.76	$5.05M	1.99	2.54 million shs	108,446 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	-12.09%	-34.63%	-76.82%	-96.19%	-98.65%
LIMN Liminatus Pharma	-1.16%	-7.84%	-1.73%	-40.44%	-95.16%
SLXN Silexion Therapeutics	-1.23%	-33.03%	-51.11%	-93.18%	-99.53%
SNGX Soligenix	-4.81%	-6.48%	-8.02%	-10.00%	-80.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$0.21 -3.8%	$1.07	$0.21 ▼ $27.15	$3.74M	1.42	356,285 shs	455,112 shs
LIMN Liminatus Pharma	$3.35 -1.9%	$4.37	$3.27 ▼ $141.50	$4.48M	4.97	339,708 shs	17,101 shs
SLXN Silexion Therapeutics	$0.17 -3.4%	$0.47	$0.16 ▼ $38.20	$945K	-0.29	3.44 million shs	485,697 shs
SNGX Soligenix	$0.34 +1.9%	$0.38	$0.28 ▼ $1.76	$5.05M	1.99	2.54 million shs	108,446 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	-12.09%	-34.63%	-76.82%	-96.19%	-98.65%
LIMN Liminatus Pharma	-1.16%	-7.84%	-1.73%	-40.44%	-95.16%
SLXN Silexion Therapeutics	-1.23%	-33.03%	-51.11%	-93.18%	-99.53%
SNGX Soligenix	-4.81%	-6.48%	-8.02%	-10.00%	-80.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENLV Enlivex Therapeutics	2.00	Hold	$247.50	115,554.21% Upside
LIMN Liminatus Pharma	1.00	Sell	N/A	N/A
SLXN Silexion Therapeutics	2.00	Hold	N/A	N/A
SNGX Soligenix	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest SLXN, SNGX, ENLV, and LIMN Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/2/2026	ENLV Enlivex Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
9/22/2026	ENLV Enlivex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D)
9/11/2026	SLXN Silexion Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/3/2026	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	SLXN Silexion Therapeutics	Maxim Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
7/21/2026	ENLV Enlivex Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
7/17/2026	SNGX Soligenix	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$122.21 per share	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	($18.13) per share	N/A
SLXN Silexion Therapeutics	N/A	N/A	N/A	N/A	$8.33 per share	N/A
SNGX Soligenix	$120K	42.11	N/A	N/A	$0.52 per share	0.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENLV Enlivex Therapeutics	$1.24B	-$8.25	N/A	N/A	N/A	N/A	N/A	N/A	11/13/2026 (Estimated)
LIMN Liminatus Pharma	-$10.21M	-$23.50	N/A	N/A	N/A	N/A	N/A	-256.58%	N/A
SLXN Silexion Therapeutics	-$11.91M	-$42.47	N/A	N/A	N/A	N/A	-563.11%	-201.73%	11/11/2026 (Estimated)
SNGX Soligenix	-$11.08M	-$0.98	N/A	N/A	N/A	N/A	-180.25%	-107.46%	11/6/2026 (Estimated)

Latest SLXN, SNGX, ENLV, and LIMN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	N/A	SLXN Silexion Therapeutics	-$9.10	N/A	N/A	N/A	N/A	N/A
11/6/2026	Q3 2026	SNGX Soligenix	-$0.12	N/A	N/A	N/A	N/A	N/A
8/15/2026	Q2 2026	SLXN Silexion Therapeutics	-$21.20	-$5.17	+$16.03	-$5.17	N/A	N/A
8/7/2026	Q2 2026	SNGX Soligenix	-$0.1550	-$0.12	+$0.0350	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A
SLXN Silexion Therapeutics	N/A	N/A	N/A	N/A	N/A
SNGX Soligenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENLV Enlivex Therapeutics	N/A	119.39	119.39
LIMN Liminatus Pharma	N/A	1.12	1.12
SLXN Silexion Therapeutics	N/A	0.94	0.94
SNGX Soligenix	N/A	2.77	2.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENLV Enlivex Therapeutics	1.02%
LIMN Liminatus Pharma	N/A
SLXN Silexion Therapeutics	10.95%
SNGX Soligenix	3.60%

Insider Ownership

Company	Insider Ownership
ENLV Enlivex Therapeutics	12.28%
LIMN Liminatus Pharma	19.40%
SLXN Silexion Therapeutics	0.30%
SNGX Soligenix	1.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENLV Enlivex Therapeutics	34	17.49 million	15.34 million	Optionable
LIMN Liminatus Pharma	1	1.34 million	1.08 million	N/A
SLXN Silexion Therapeutics	14	5.56 million	5.54 million	N/A
SNGX Soligenix	14	14.82 million	14.54 million	Not Optionable

SLXN, SNGX, ENLV, and LIMN Headlines

Recent News About These Companies

Head to Head Comparison: Cartesian Therapeutics (NASDAQ:RNAC) versus Soligenix (NASDAQ:SNGX)

October 4, 2026 | americanbankingnews.com

SNGX: Applying for Vaccine Development Funding for Ebola Vaccine

August 12, 2026 | finance.yahoo.com

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

August 7, 2026 | prnewswire.com

Soligenix Expands At-the-Market Equity Offering Capacity

June 26, 2026 | tipranks.com

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

June 8, 2026 | prnewswire.com

Soligenix Expands At-The-Market Equity Financing Capacity

May 28, 2026 | tipranks.com

SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy

May 27, 2026 | finance.yahoo.com

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

May 26, 2026 | prnewswire.com

SOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

May 8, 2026 | finanznachrichten.de

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

May 8, 2026 | prnewswire.com

SNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatment

April 29, 2026 | msn.com

SNGX phase 3 trial halted on HyBryte

April 29, 2026 | msn.com

SOLIGENIX, INC.: Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell Lymphoma

April 28, 2026 | finanznachrichten.de

SNGX phase 3 trial halted — HyBryte setback puts strategy in question

April 28, 2026 | msn.com

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

April 28, 2026 | prnewswire.com

Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach

April 23, 2026 | finance.yahoo.com

Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach

April 23, 2026 | usatoday.com

Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

April 20, 2026 | financial-news.co.uk

Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

April 20, 2026 | finance.yahoo.com

Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

April 17, 2026 | financial-news.co.uk

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN, SNGX, ENLV, and LIMN Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

$0.21 -0.01 (-3.78%)

As of 02:48 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Liminatus Pharma NASDAQ:LIMN

$3.34 -0.07 (-1.91%)

As of 02:47 PM Eastern

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Silexion Therapeutics NASDAQ:SLXN

$0.17 -0.01 (-3.41%)

As of 02:49 PM Eastern

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Soligenix NASDAQ:SNGX

$0.34 +0.01 (+1.85%)

As of 02:44 PM Eastern

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLXN, SNGX, ENLV, and LIMN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLXN, SNGX, ENLV, and LIMN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLXN, SNGX, ENLV, and LIMN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN, SNGX, ENLV, and LIMN Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

Liminatus Pharma NASDAQ:LIMN

Silexion Therapeutics NASDAQ:SLXN

Soligenix NASDAQ:SNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLXN, SNGX, ENLV, and LIMN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLXN, SNGX, ENLV, and LIMN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLXN, SNGX, ENLV, and LIMN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN, SNGX, ENLV, and LIMN Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

Liminatus Pharma NASDAQ:LIMN

Silexion Therapeutics NASDAQ:SLXN

Soligenix NASDAQ:SNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools